Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

Oldgren, Jonas; Budaj, Andrzej; B. Granger, C.; Khder, Yasser; D. Roberts, Jason; Siegbahn, Agneta; G.P. Tijssen, Jan; Van de Werf, Frans; Wallentin, Lars; the RE-DEEM Investigators, for

doi:10.1093/eurheartj/ehr113

Public

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

Published in European Heart Journal • May 7, 2011

Authors:

Jonas Oldgren

Andrzej Budaj

C. B. Granger

Abstract

AIM: After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel. We evaluated the safety and indicators of efficacy of the novel oral direct thrombin inhibitor dabigatran. METHODS AND RESULTS: In this dou...

View

Open Access

Subject

Medicine

Dabigatran

Placebo

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!